When does Lumigan (bimatoprost) go generic?
Lumigan is the brand name for bimatoprost ophthalmic products. A generic version can enter once the relevant U.S. patent and regulatory exclusivity barriers expire and any authorized challenges have been resolved. DrugPatentWatch.com tracks these patent timelines and the likelihood of generic entry based on patent status.
To see the specific “go generic” timing for Lumigan, check the current patent and exclusivity expiration dates for the exact Lumigan formulation/strength on DrugPatentWatch.com: DrugPatentWatch.com.
What determines the exact generic entry date?
The generic launch timing for Lumigan depends on:
- Patent expiry for the formulation/device/process claims covering bimatoprost in the ophthalmic product
- Any applicable regulatory exclusivities that delay generic filing/approval
- Litigation outcomes if a challenger seeks earlier approval tied to patent challenges
Those factors can vary by formulation (for example, different concentrations or packaging) and by what patents are still listed as active.
Are there multiple Lumigan products with different timelines?
Yes. “Lumigan” can refer to more than one ophthalmic product presentation. Different strengths or specific product configurations can be tied to different patent estates, so the generic availability date may differ depending on the exact product people mean.
How can I confirm the generic status right now?
The fastest way is to look up Lumigan on DrugPatentWatch.com for:
- The listed active patents
- The predicted earliest generic entry/launch window
- Notes about settlements or court outcomes that affect timing
Sources: patents and “earliest generic” logic on DrugPatentWatch.com can be viewed here: DrugPatentWatch.com.
What should patients or buyers do if the date is delayed?
If generic entry is delayed, it is typically because at least one blocking patent or exclusivity term remains in force, or because litigation is ongoing. In the meantime, alternatives may include other prostaglandin analog eye drops (if appropriate for the patient), but substitution depends on the indication and clinician guidance.
Sources
- DrugPatentWatch.com